Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28165622 | 0.86 | ALPL (0.33) | ALPL | |
| SCHEMBL7003394 | 0.81 | ALOX5AP (0.40) | NOS3NOS1NOS2MAPT | |
| SCHEMBL21775851 | 0.79 | KMO (0.42) | IDO1ALPLMKNK2MAPT | |
| SCHEMBL3339364 | 0.76 | IKBKE (0.38) | ALPLMKNK1MKNK2TP53MAPT | |
| SCHEMBL14726281 | 0.75 | CASP1 (0.44) | IDO1TDO2TP53MAPT | |
| SCHEMBL3340666 | 0.73 | CHEK1 (0.43) | ALPLMAPT | |
| SCHEMBL15656631 | 0.72 | NOTUM (0.44) | IDO1TDO2ALPLMAPT | |
| SCHEMBL14726272 | 0.72 | KMO (0.42) | TP53MAPT | |
| SCHEMBL10626865 | 0.71 | NOTUM (0.32) | — | |
| SCHEMBL474802 | 0.71 | ALPL (0.54) | ALPLMKNK1MKNK2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-03-30 | — | — | US | disclosed |
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | GABRA5, P2RX5, P2RY1 | IDO1 1005/4885TDO2 2209/4885ALPL 2006/4885 |
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, P2RX5, P2RY1 | IDO1 1005/4885TDO2 2209/4885ALPL 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.